@article{708772546fcd437fbf3b4416f4602d83,
title = "Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer",
abstract = "Triple-negative breast cancer (TNBC) is the deadliest form of breast cancer. Unlike other types of breast cancer that can be effectively treated by targeted therapies, no such targeted therapy exists for all TNBC patients. The ADAR1 enzyme carries out A-to-I editing of RNA to prevent sensing of endogenous double-stranded RNAs. ADAR1 is highly expressed in breast cancer including TNBC. Here, we demonstrate that expression of ADAR1, specifically its p150 isoform, is required for the survival of TNBC cell lines. In TNBC cells, knockdown of ADAR1 attenuates proliferation and tumorigenesis. Moreover, ADAR1 knockdown leads to robust translational repression. ADAR1-dependent TNBC cell lines also exhibit elevated IFN stimulated gene expression. IFNAR1 reduction significantly rescued the proliferative defects of ADAR1 loss. These findings establish ADAR1 as a novel therapeutic target for TNBC tumors.",
author = "Kung, {Che Pei} and Cottrell, {Kyle A.} and Sua Ryu and Bramel, {Emily R.} and Kladney, {Raleigh D.} and Bao, {Emily A.} and Freeman, {Eric C.} and Thwisha Sabloak and Leonard Maggi and Weber, {Jason D.}",
note = "Funding Information: Acknowledgements This work was supported by R01CA190986 (JDW), F32GM131514 (KAC), and TL1TR002344 (C-PK) from the National Institute of Health, and W81XWH-18-1-0025 from the Department of Defense (JDW). This work was supported by the Longer Life Foundation: A RGA/Washington University partnership. We thank Kazuko Nishikura (The Wistar Institute) for providing ADAR1 expressing constructs. The results shown here are in whole or part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga. Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2021",
month = jan,
day = "7",
doi = "10.1038/s41388-020-01515-5",
language = "English",
volume = "40",
pages = "189--202",
journal = "Oncogene",
issn = "0950-9232",
number = "1",
}